Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) Director Gary L. Crocker purchased 36,000 shares of Merrimack Pharmaceuticals stock on the open market in a transaction that occurred on Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) weekly performance is -7.13%. On last trading day company shares ended up $7.16. Analysts mean target price for the company is $13.30. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) distance from 50-day simple moving average (SMA50) is 8.74%.
Omeros Corporation (NASDAQ:OMER) Director Peter A. Md Demopulos acquired 6,153 shares of the stock in a transaction dated Tuesday, June 24th. The stock was purchased at an average price of $16.20 per share, with a total value of $99,678.60. Following the acquisition, the director now directly owns 181,220 shares in the company, valued at approximately $2,935,764. Omeros Corporation (NASDAQ:OMER) shares advanced 4.43% in last trading session and ended the day on $16.04. OMER return on assets is -170.50%.Omeros Corporation (NASDAQ:OMER) quarterly performance is 33.78%.
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) Director John Maraganore bought 2,300 shares of Agios Pharmaceuticals stock in a transaction dated Monday, June 23rd. The stock was purchased at an average cost of $43.98 per share, for a total transaction of $101,154.00. Following the completion of the acquisition, the director now directly owns 48,883 shares of the company’s stock, valued at approximately $2,149,874. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares moved down -0.32% in last trading session and was closed at $43.88, while trading in range of $43.53 – $45.18. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) year to date (YTD) performance is 83.22%.
Insys Therapeutics Inc. (NASDAQ:INSY) Director John N. Kapoor bought 5,000 shares of the company’s stock on the open market in a transaction dated Friday, June 13th. The stock was purchased at an average cost of $25.44 per share, for a total transaction of $127,200.00. Following the transaction, the director now directly owns 15,991 shares of the company’s stock, valued at approximately $406,811. Insys Therapeutics Inc. (NASDAQ:INSY) ended the last trading day at $29.01. Company weekly volatility is calculated as 6.92% and price to cash ratio as 21.17.Insys Therapeutics Inc. (NASDAQ:INSY) showed a negative weekly performance of -2.32%.
BioTime Inc. (NYSE:BTX) Director Broadwood Partners Lp bought 1,000,000 shares of the company’s stock in a transaction dated Monday, June 16th. The stock was purchased at an average price of $2.50 per share, for a total transaction of $2,500,000.00. BioTime, Inc. (NYSEMKT:BTX) weekly performance is -5.81%. On last trading day company shares ended up $3.08. BioTime, Inc. (NYSEMKT:BTX) distance from 50-day simple moving average (SMA50) is 13.45%.